MIR140-related spondyloepiphyseal dysplasia
MIR one-forty related spondyloepiphyseal dysplasia
Also known as: SED-MIR140, MIR140-SED
At a Glance
What is MIR140-related spondyloepiphyseal dysplasia?
MIR140-related spondyloepiphyseal dysplasia is a rare genetic disorder that affects bone growth, particularly in the spine and the ends of long bones. It primarily impacts the musculoskeletal system, leading to short stature and skeletal abnormalities. The condition is caused by mutations in the MIR140 gene, which plays a role in cartilage development. Over time, individuals may experience joint pain and stiffness, with early symptoms often including delayed growth and physical development. As the condition progresses, affected individuals might develop more pronounced skeletal deformities and mobility issues. Early diagnosis is crucial to manage symptoms and improve quality of life. The disorder can place a significant emotional and financial burden on families, as ongoing medical care and support are often needed. Prognosis varies, but many individuals lead active lives with appropriate interventions. Daily life may include physical therapy and regular medical check-ups to monitor bone health. Adaptations at home and school can help manage physical limitations. Support groups and genetic counseling can provide valuable resources for affected families. Understanding the condition can empower families to make informed decisions about care and lifestyle adjustments.
Medical Definition
MIR140-related spondyloepiphyseal dysplasia is a genetic disorder characterized by mutations in the MIR140 gene, affecting cartilage development and bone growth. Pathologically, it involves abnormal endochondral ossification, leading to skeletal dysplasia. Histological findings may show disorganized cartilage and delayed ossification processes. It is classified under spondyloepiphyseal dysplasias, a group of disorders affecting the spine and epiphyseal growth plates. Epidemiologically, it is an extremely rare condition with a prevalence of approximately 1 in 1,000,000. The disease course involves progressive skeletal abnormalities, with symptoms typically emerging in childhood and potentially leading to significant physical impairment if not managed effectively.
MIR140-related spondyloepiphyseal dysplasia Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Short stature manifests as a significantly reduced height compared to age-matched peers. This occurs due to impaired growth of the long bones and vertebrae, primarily caused by mutations affecting cartilage development. Over time, the growth rate slows down, leading to a noticeable height discrepancy by adolescence. This affects daily life by limiting physical activities and can be managed with growth hormone therapy in some cases.
Joint pain presents as discomfort or aching in the joints, particularly in the hips and knees. It is caused by abnormal cartilage formation leading to joint misalignment and early degenerative changes. The pain often worsens with age and increased physical activity. Daily life is impacted by reduced mobility and physical therapy can help alleviate symptoms.
Spinal deformities such as scoliosis or kyphosis are common and manifest as abnormal curvature of the spine. These deformities result from uneven growth of the vertebrae due to defective cartilage. Over time, the curvature can become more pronounced, potentially leading to respiratory issues. Treatment may include bracing or surgery to improve posture and prevent complications.
Common
Hip dysplasia is characterized by an improperly formed hip joint, leading to instability. This condition arises from abnormal development of the acetabulum and femoral head. As the individual grows, it can lead to increased wear and tear, resulting in pain and limited range of motion. Early intervention with physical therapy or surgery can improve joint function and reduce discomfort.
Vision problems may include nearsightedness or astigmatism, presenting as difficulty seeing objects at a distance or blurred vision. These issues are caused by abnormal growth of the eye structures due to connective tissue defects. Vision may progressively worsen over time, affecting daily tasks such as reading and driving. Corrective lenses or surgery can help manage these symptoms.
Hearing loss can manifest as difficulty hearing conversations or sounds, often due to conductive hearing issues. This occurs because of malformations in the middle ear structures linked to skeletal dysplasia. Hearing loss may become more pronounced with age, impacting communication and social interactions. Hearing aids or surgical interventions can improve hearing ability.
Less Common
Respiratory issues may present as shortness of breath or frequent respiratory infections. These problems are linked to thoracic cage deformities and reduced lung capacity due to spinal abnormalities. Over time, respiratory function may decline, particularly if spinal curvature progresses. Management includes respiratory therapy and monitoring to prevent complications.
Dental abnormalities can include misaligned teeth or delayed eruption of permanent teeth. These issues arise from altered jaw and tooth development associated with connective tissue disorders. As the child grows, dental problems may lead to difficulties in chewing and speech. Orthodontic treatment and regular dental care can help address these concerns.
What Causes MIR140-related spondyloepiphyseal dysplasia?
MIR140-related spondyloepiphyseal dysplasia is caused by mutations in the MIR140 gene, located on chromosome 16q22. The MIR140 gene encodes a microRNA that plays a crucial role in the regulation of cartilage development and homeostasis. Mutations in MIR140 can lead to the production of a dysfunctional microRNA, which impairs its ability to regulate target mRNA expression. This disruption in microRNA function results in the dysregulation of genes involved in chondrocyte proliferation and differentiation. Consequently, there is an abnormal development and maintenance of the extracellular matrix in cartilage tissue. The impaired cartilage structure affects the integrity and function of joints and growth plates, leading to skeletal abnormalities. Neuroinflammation may be triggered as a secondary response to tissue damage, exacerbating the condition. The degeneration of cartilage and other connective tissues can result in the progressive deterioration of joint function and mobility. Symptoms typically manifest as disproportionate short stature, spinal deformities, and joint pain, reflecting the primary sites of cartilage dysfunction. The variability in disease severity among patients may be attributed to the specific nature of the mutations, genetic background, and environmental factors. Some patients may experience more severe skeletal deformities, while others have milder symptoms. The involvement of immune responses can further influence the progression and severity of the disease. Understanding the precise molecular mechanisms and pathways affected by MIR140 mutations is crucial for developing targeted therapies. Research is ongoing to explore potential interventions that could mitigate the effects of these mutations and improve patient outcomes.
How is MIR140-related spondyloepiphyseal dysplasia Diagnosed?
Typical age of diagnosis: MIR140-related spondyloepiphyseal dysplasia is typically diagnosed in early childhood when growth abnormalities and skeletal deformities become apparent.
The clinician looks for disproportionate short stature, joint pain, and skeletal deformities. A detailed family history is crucial to identify any hereditary patterns. Physical examination may reveal joint stiffness, spinal abnormalities, and limb length discrepancies. This step helps to differentiate spondyloepiphyseal dysplasia from other growth disorders.
X-rays are the primary imaging modality used to assess bone structure. Specific abnormalities such as epiphyseal dysplasia, vertebral flattening, and metaphyseal changes are visible. These findings confirm the diagnosis by illustrating characteristic skeletal changes. Imaging also helps exclude other conditions like osteoarthritis or congenital skeletal disorders.
Routine blood tests may include markers of bone turnover and calcium levels. Biomarkers such as alkaline phosphatase may be elevated. Abnormal results indicate altered bone metabolism, guiding further genetic testing. Laboratory findings help rule out metabolic bone diseases.
Genetic testing involves sequencing the MIR140 gene. Mutations such as deletions or point mutations are identified. These results confirm the diagnosis by linking clinical features to genetic alterations. Genetic testing also provides information for family counseling regarding inheritance patterns.
MIR140-related spondyloepiphyseal dysplasia Treatment Options
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to manage pain and inflammation. They work by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis. Commonly used NSAIDs include ibuprofen and naproxen. Clinical evidence supports their efficacy in alleviating joint pain, though they do not alter disease progression. Side effects may include gastrointestinal irritation and renal impairment.
Techniques such as stretching, strengthening exercises, and joint mobilization are utilized. The therapeutic goals are to improve mobility, reduce pain, and enhance functional capacity. Sessions are typically conducted 2-3 times per week over several months. Measurable outcomes include increased range of motion and improved gait. Long-term benefits include better quality of life and reduced disability.
Surgery is indicated for severe skeletal deformities affecting function. The procedure involves cutting and realigning bones to correct deformities. Expected benefits include improved alignment and function. Surgical risks include infection, nerve damage, and non-union of bones. Post-operative care requires physical therapy and regular follow-up.
The care team includes orthopedic specialists, physical therapists, and genetic counselors. Interventions focus on managing symptoms, optimizing mobility, and providing genetic counseling. Psychosocial support strategies involve counseling and support groups for patients and families. Family education covers disease management and genetic implications. Long-term monitoring includes regular assessments of growth and skeletal health.
When to See a Doctor for MIR140-related spondyloepiphyseal dysplasia
- Severe breathing difficulties — this could indicate a critical respiratory issue requiring immediate medical attention.
- Sudden loss of mobility — this may suggest a severe spinal or neurological complication that needs urgent evaluation.
- Acute chest pain — could be a sign of cardiovascular involvement, which is an emergency situation.
- Persistent joint pain — may indicate worsening of joint deterioration and should be assessed by a healthcare provider.
- Noticeable growth delays — could signify progression of skeletal abnormalities and warrants a medical review.
- Frequent falls — may suggest balance or coordination issues that need further investigation.
- Mild joint stiffness — monitor for any increase in severity or frequency and discuss with a doctor if it worsens.
- Occasional fatigue — keep track of energy levels and ensure adequate rest; consult a doctor if it becomes persistent.
MIR140-related spondyloepiphyseal dysplasia — Frequently Asked Questions
Is this condition hereditary?
MIR140-related spondyloepiphyseal dysplasia is typically inherited in an autosomal dominant pattern. This means there is a 50% chance of passing it to children if one parent is affected. De novo mutations can occur, meaning the condition can appear in individuals with no family history. Carrier status is not applicable as it is not a recessive condition. Genetic counseling is recommended for affected individuals and their families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the severity and age of onset of the condition. Early diagnosis and management of symptoms can improve outcomes. Complications such as respiratory issues or severe joint problems can affect mortality. Treatment can help manage symptoms but may not significantly extend life expectancy. Realistic expectations should focus on quality of life and managing symptoms effectively.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, imaging studies, and genetic testing. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity of the condition. Specialists such as geneticists, orthopedists, and rheumatologists are usually consulted. Delayed diagnosis is common due to symptom overlap with other conditions. Genetic testing ultimately confirms the diagnosis.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy being one of the most promising areas. Novel approaches such as targeted molecular therapies are also being explored. Clinical trials can be found on ClinicalTrials.gov by searching for the condition. Patients should ask their doctors about eligibility for trials and potential benefits. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
Mobility may be significantly impacted, requiring assistive devices for walking and self-care. Educational accommodations may be necessary due to physical limitations. Social and emotional challenges include coping with chronic pain and potential isolation. The condition can place a significant burden on families, both emotionally and financially. Supportive therapies and adaptations, such as physical therapy and home modifications, can greatly assist daily living.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Spondyloepiphyseal Dysplasia Tarda.
Bencherifa S, Mounach A, Bezza A · J Clin Rheumatol · 2021 · PMID: 31693650
- 2.Skeletal deterioration in COL2A1-related spondyloepiphyseal dysplasia occurs prior to osteoarthritis.
Rolvien T, Yorgan TA, Kornak U et al. · Osteoarthritis Cartilage · 2020 · PMID: 31958497
- 3.Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing.
Merico D, Roifman M, Braunschweig U et al. · Nat Commun · 2015 · PMID: 26522830
- 4.Spondyloepiphyseal dysplasia congenita.
Turner LM, Steffensen TS, Leroy J et al. · Fetal Pediatr Pathol · 2010 · PMID: 20055564
- 5.Schwartz-Jampel syndrome.
Pascuzzi RM · Semin Neurol · 1991 · PMID: 1947489
- 6.Spondyloepiphyseal dysplasia congenita.
Spranger JW, Langer LO Jr · Radiology · 1970 · PMID: 5412797
- 7.Spondyloepiphyseal dysplasia.
Spranger J, Langer LO · Birth Defects Orig Artic Ser · 1974 · PMID: 4213775
- 8.Schwartz-Jampel Syndrome.
Mathur N, Ghosh PS · Pediatr Neurol · 2017 · PMID: 28129933
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-27